neoplasms

Summary

Summary: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Top Publications

  1. ncbi The hallmarks of cancer
    D Hanahan
    Department of Biochemistry, Hormone Research Institute, University of California at San Francisco, 94143, USA
    Cell 100:57-70. 2000
  2. pmc The epigenomics of cancer
    Peter A Jones
    Department of Urology, Biochemistry, and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cell 128:683-92. 2007
  3. ncbi DNA methylation and human disease
    Keith D Robertson
    Department of Biochemistry and Molecular Biology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA
    Nat Rev Genet 6:597-610. 2005
  4. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  5. ncbi The protein kinase complement of the human genome
    G Manning
    SUGEN Inc, 230 East Grand Avenue, South San Francisco, CA 94080, USA
    Science 298:1912-34. 2002
  6. ncbi Hallmarks of cancer: the next generation
    Douglas Hanahan
    The Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences, EPFL, Lausanne CH 1015, Switzerland
    Cell 144:646-74. 2011
  7. ncbi MicroRNA expression profiles classify human cancers
    Jun Lu
    Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02141, USA
    Nature 435:834-8. 2005
  8. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
  9. pmc Understanding the Warburg effect: the metabolic requirements of cell proliferation
    Matthew G Vander Heiden
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 324:1029-33. 2009
  10. ncbi Oncomirs - microRNAs with a role in cancer
    Aurora Esquela-Kerscher
    Yale University, Department of Molecular, Cellular and Developmental Biology, 266 Whitney Avenue, New Haven, Connecticut 06520, USA
    Nat Rev Cancer 6:259-69. 2006

Detail Information

Publications261 found, 100 shown here

  1. ncbi The hallmarks of cancer
    D Hanahan
    Department of Biochemistry, Hormone Research Institute, University of California at San Francisco, 94143, USA
    Cell 100:57-70. 2000
  2. pmc The epigenomics of cancer
    Peter A Jones
    Department of Urology, Biochemistry, and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cell 128:683-92. 2007
    ....
  3. ncbi DNA methylation and human disease
    Keith D Robertson
    Department of Biochemistry and Molecular Biology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA
    Nat Rev Genet 6:597-610. 2005
    ..The study of these diseases has provided new and fundamental insights into the roles that DNA methylation and other epigenetic modifications have in development and normal cellular homeostasis...
  4. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  5. ncbi The protein kinase complement of the human genome
    G Manning
    SUGEN Inc, 230 East Grand Avenue, South San Francisco, CA 94080, USA
    Science 298:1912-34. 2002
    ..We also identified 106 protein kinase pseudogenes. Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons...
  6. ncbi Hallmarks of cancer: the next generation
    Douglas Hanahan
    The Swiss Institute for Experimental Cancer Research ISREC, School of Life Sciences, EPFL, Lausanne CH 1015, Switzerland
    Cell 144:646-74. 2011
    ..Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer...
  7. ncbi MicroRNA expression profiles classify human cancers
    Jun Lu
    Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02141, USA
    Nature 435:834-8. 2005
    ..These findings highlight the potential of miRNA profiling in cancer diagnosis...
  8. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
    ..Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate...
  9. pmc Understanding the Warburg effect: the metabolic requirements of cell proliferation
    Matthew G Vander Heiden
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 324:1029-33. 2009
    ..A better understanding of the mechanistic links between cellular metabolism and growth control may ultimately lead to better treatments for human cancer...
  10. ncbi Oncomirs - microRNAs with a role in cancer
    Aurora Esquela-Kerscher
    Yale University, Department of Molecular, Cellular and Developmental Biology, 266 Whitney Avenue, New Haven, Connecticut 06520, USA
    Nat Rev Cancer 6:259-69. 2006
    ..miRNAs have been shown to repress the expression of important cancer-related genes and might prove useful in the diagnosis and treatment of cancer...
  11. ncbi MicroRNA signatures in human cancers
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Nat Rev Cancer 6:857-66. 2006
    ..In addition, profiling has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer...
  12. pmc Inflammation and cancer
    Lisa M Coussens
    Cancer Research Institute, Department of Pathology, University of California, San Francisco, California 94143, USA
    Nature 420:860-7. 2002
    ..These insights are fostering new anti-inflammatory therapeutic approaches to cancer development...
  13. ncbi Cancer-related inflammation
    Alberto Mantovani
    Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, 20089 Milan, Italy
    Nature 454:436-44. 2008
    ..The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment...
  14. ncbi Stem cells, cancer, and cancer stem cells
    T Reya
    Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Palo Alto, California 94305, USA
    Nature 414:105-11. 2001
    ....
  15. pmc A microRNA expression signature of human solid tumors defines cancer gene targets
    Stefano Volinia
    Department of Molecular Virology, Immunology, and Medical Genetics and Cancer Comprehensive Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 103:2257-61. 2006
    ..Our results indicate that miRNAs are extensively involved in cancer pathogenesis of solid tumors and support their function as either dominant or recessive cancer genes...
  16. pmc Immunity, inflammation, and cancer
    Sergei I Grivennikov
    Departments of Pharmacology and Pathology, University of California, San Diego, La Jolla, 92093, USA
    Cell 140:883-99. 2010
    ..This review outlines the principal mechanisms that govern the effects of inflammation and immunity on tumor development and discusses attractive new targets for cancer therapy and prevention...
  17. ncbi Mutations of the BRAF gene in human cancer
    Helen Davies
    Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA, UK
    Nature 417:949-54. 2002
    ..As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma...
  18. ncbi Epithelial-mesenchymal transitions in tumour progression
    Jean Paul Thiery
    Centre National Recherche Scientifique Unité Mixte Recherche, 144 Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Nat Rev Cancer 2:442-54. 2002
  19. pmc A census of human cancer genes
    P Andrew Futreal
    Cancer Genome Project, Human Genome Analysis Group and Pfam Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton Cambs, CB10 1SA, UK
    Nat Rev Cancer 4:177-83. 2004
  20. ncbi Regulation of cancer cell metabolism
    Rob A Cairns
    The Campbell Family Cancer Research Institute, Toronto, ON M56 2M9, Canada
    Nat Rev Cancer 11:85-95. 2011
    ....
  21. ncbi Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
    Kornelia Polyak
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 9:265-73. 2009
    ....
  22. pmc Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
    George Adrian Calin
    Department of Microbiology and Immunology, Division of Clinical Pharmacology, Biostatistics Section, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 101:2999-3004. 2004
    ..These data provide a catalog of miR genes that may have roles in cancer and argue that the full complement of miRs in a genome may be extensively involved in cancers...
  23. pmc Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
    George Adrian Calin
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 99:15524-9. 2002
    ..Detailed deletion and expression analysis shows that miR15 and miR16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority ( approximately 68%) of CLL cases...
  24. ncbi Targeting HIF-1 for cancer therapy
    Gregg L Semenza
    McKusick Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 3914, USA
    Nat Rev Cancer 3:721-32. 2003
    ..In preclinical studies, inhibition of HIF-1 activity has marked effects on tumour growth. Efforts are underway to identify inhibitors of HIF-1 and to test their efficacy as anticancer therapeutics...
  25. pmc The cancer genome
    Michael R Stratton
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 458:719-24. 2009
    ..These studies will provide us with a detailed and comprehensive perspective on how individual cancers have developed...
  26. pmc Matrix metalloproteinases: regulators of the tumor microenvironment
    Kai Kessenbrock
    Department of Anatomy and Biomedical Sciences Program, University of California, San Francisco, CA 94143 0452, USA
    Cell 141:52-67. 2010
    ..These aspects of MMP function are reorienting our approaches to cancer therapy...
  27. ncbi The phosphatidylinositol 3-Kinase AKT pathway in human cancer
    Igor Vivanco
    Department of Medicine and Molecular Biology Institute, UCLA School of Medicine, 11 935 Factor Building, 10833 LeConte Avenue, Los Angeles, California 90095, USA
    Nat Rev Cancer 2:489-501. 2002
  28. ncbi The phosphoinositide 3-kinase pathway
    Lewis C Cantley
    Department of Cell Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115 5713, USA
    Science 296:1655-7. 2002
    ..The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapuetic intervention...
  29. pmc COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
    Simon A Forbes
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA Cambridge, UK
    Nucleic Acids Res 39:D945-50. 2011
    ..With all genomic information recently updated to GRCh37, COSMIC integrates many diverse types of mutation information and is making much closer links with Ensembl and other data resources...
  30. pmc Causes and consequences of microRNA dysregulation in cancer
    Carlo M Croce
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Medical Center, 410 West 10th Avenue, Columbus, OH 43210, USA
    Nat Rev Genet 10:704-14. 2009
    ....
  31. ncbi Cancer metastasis: building a framework
    Gaorav P Gupta
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 127:679-95. 2006
    ..Recent conceptual and technological advances promote our understanding of the origins and nature of cancer metastasis...
  32. ncbi Complex networks orchestrate epithelial-mesenchymal transitions
    Jean Paul Thiery
    Centre National de la Recherche Scientifique CNRS Unité Mixte Recherche UMR 144 and Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Nat Rev Mol Cell Biol 7:131-42. 2006
    ..Understanding how mesenchymal cells arise from an epithelial default status will also have a strong impact in unravelling the mechanisms that control fibrosis and cancer progression...
  33. ncbi Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
    Jane E Visvader
    VBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia
    Nat Rev Cancer 8:755-68. 2008
    ..The clinical relevance of CSCs remains a fundamental issue but preliminary findings indicate that specific targeting may be possible...
  34. pmc The landscape of somatic copy-number alteration across human cancers
    Rameen Beroukhim
    Cancer Program and Medical and Population Genetics Group, The Broad Institute of M I T and Harvard, 7 Cambridge Center
    Nature 463:899-905. 2010
    ..Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types...
  35. ncbi Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Hannah Farmer
    Cancer Research UK Gene Function and Regulation Group, London, UK
    Nature 434:917-21. 2005
    ..These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer...
  36. pmc Myeloid-derived suppressor cells as regulators of the immune system
    Dmitry I Gabrilovich
    Department of Oncologic Sciences, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Nat Rev Immunol 9:162-74. 2009
    ..In this Review, we discuss the origin, mechanisms of expansion and suppressive functions of MDSCs, as well as the potential to target these cells for therapeutic benefit...
  37. ncbi Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
    Alberto Mantovani
    Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, I 20157 Milan, Italy
    Trends Immunol 23:549-55. 2002
    ..These functionally polarized cells, and similarly oriented or immature dendritic cells present in tumors, have a key role in subversion of adaptive immunity and in inflammatory circuits that promote tumor growth and progression...
  38. pmc The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
    Sun Mi Park
    The Ben May Department for Cancer Research, The University of Chicago, Chicago, Illinois 60637, USA
    Genes Dev 22:894-907. 2008
    ..Conversely, inhibition of miR-200 reduced E-cadherin expression, increased expression of Vimentin, and induced EMT. Our data identify miR-200 as a powerful marker and determining factor of the epithelial phenotype of cancer cells...
  39. ncbi Upstream and downstream of mTOR
    Nissim Hay
    Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, 60607, USA
    Genes Dev 18:1926-45. 2004
    ..We also summarize the roles of mTOR in the control of cell growth and proliferation, as well as its relevance to cancer and synaptic plasticity...
  40. ncbi Global cancer statistics, 2002
    D Max Parkin
    Unit of Descriptive Epidemiology, International Agency for Research on Cancer, Lyon, France
    CA Cancer J Clin 55:74-108. 2005
    ..Most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention...
  41. ncbi Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion
    Robert D Schreiber
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    Science 331:1565-70. 2011
    ..Here, we discuss a unifying conceptual framework called "cancer immunoediting," which integrates the immune system's dual host-protective and tumor-promoting roles...
  42. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  43. ncbi Inflammation and cancer: back to Virchow?
    F Balkwill
    ICRF Translational Oncology Laboratory, St Bartholomew s and Royal London School of Medicine and Dentistry, UK
    Lancet 357:539-45. 2001
    ..In this article we have provided a rationale for the use of cytokine and chemokine blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemoprevention and treatment of malignant diseases...
  44. ncbi Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults
    Eugenia E Calle
    Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta 30329, USA
    N Engl J Med 348:1625-38. 2003
    ..The influence of excess body weight on the risk of death from cancer has not been fully characterized...
  45. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  46. ncbi Cancer genes and the pathways they control
    Bert Vogelstein
    Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Med 10:789-99. 2004
    ..The purposes of this review are to highlight examples of progress in these areas, indicate where knowledge is scarce and point out fertile grounds for future investigation...
  47. pmc TGFbeta in Cancer
    Joan Massague
    Cancer Biology and Genetics Program, and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 134:215-30. 2008
    ..The mechanistic basis and clinical relevance of TGFbeta's role in cancer is becoming increasingly clear, paving the way for a better understanding of the complexity and therapeutic potential of this pathway...
  48. pmc An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
    Ittai Ben-Porath
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA
    Nat Genet 40:499-507. 2008
    ....
  49. pmc A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
    Laura Poliseno
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 465:1033-8. 2010
    ..These findings attribute a novel biological role to expressed pseudogenes, as they can regulate coding gene expression, and reveal a non-coding function for mRNAs...
  50. pmc Patterns of somatic mutation in human cancer genomes
    Christopher Greenman
    Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
    Nature 446:153-8. 2007
    ..Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated...
  51. ncbi Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
    Hector Peinado
    Departamento de Bioquimica, Facultad de Medicina, Universidad Autonoma de Madrid UAM, Instituto de Investigaciones Biomedicas Alberto Sols CSIC UAM, Arturo Duperier 4, 28029 Madrid, Spain
    Nat Rev Cancer 7:415-28. 2007
    ....
  52. ncbi Targeting PI3K signalling in cancer: opportunities, challenges and limitations
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA
    Nat Rev Cancer 9:550-62. 2009
    ..I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development...
  53. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
    ..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
  54. pmc Predicting the functional impact of protein mutations: application to cancer genomics
    Boris Reva
    Computational Biology Center, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Nucleic Acids Res 39:e118. 2011
    ..In addition, we estimate that at least 5% of cancer-relevant mutations involve switch of function, rather than simply loss or gain of function...
  55. ncbi Defining the role of mTOR in cancer
    David A Guertin
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 02141, USA
    Cancer Cell 12:9-22. 2007
    ..We further discuss the use of rapamycin in oncology and conclude with a discussion on the future of mTOR-targeted therapy...
  56. ncbi The fundamental role of epigenetic events in cancer
    Peter A Jones
    USC Norris Comprehensive Cancer Center, Department of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, MS 8302L, Los Angeles, California 90089 9181, USA
    Nat Rev Genet 3:415-28. 2002
    ..In this review, we discuss these epigenetic events and the molecular alterations that might cause them and/or underlie altered gene expression in cancer...
  57. pmc A comprehensive catalogue of somatic mutations from a human cancer genome
    Erin D Pleasance
    Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 463:191-6. 2010
    ..The results illustrate the power of a cancer genome sequence to reveal traces of the DNA damage, repair, mutation and selection processes that were operative years before the cancer became symptomatic...
  58. ncbi New functions for the matrix metalloproteinases in cancer progression
    Mikala Egeblad
    Department of Anatomy, University of California at San Francisco, 94143 0452, USA
    Nat Rev Cancer 2:161-74. 2002
    ..With this knowledge in hand, can we rethink the use of MMP inhibitors in the clinic?..
  59. pmc Microenvironmental regulation of metastasis
    Johanna A Joyce
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, USA
    Nat Rev Cancer 9:239-52. 2009
    ..This Review describes experimental data demonstrating the role of the microenvironment in metastasis, identifies areas for future research and suggests possible new therapeutic avenues...
  60. ncbi Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis
    Jing Yang
    Department of Pharmacology and Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0636, USA
    Dev Cell 14:818-29. 2008
    ..Studies in both fields are critical for our molecular understanding of cell migration and morphogenesis...
  61. ncbi Why do cancers have high aerobic glycolysis?
    Robert A Gatenby
    Department of Radiology, University of Arizona, Tucson, Arizona 85721, USA
    Nat Rev Cancer 4:891-9. 2004
    ..Subsequent cell populations with upregulated glycolysis and acid resistance have a powerful growth advantage, which promotes unconstrained proliferation and invasion...
  62. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
    ....
  63. ncbi Fibroblasts in cancer
    Raghu Kalluri
    Center for Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 6:392-401. 2006
    ..Fibroblasts are therefore a key determinant in the malignant progression of cancer and represent an important target for cancer therapies...
  64. doi Epigenetics in cancer
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Research Center, Madrid, Spain
    N Engl J Med 358:1148-59. 2008
  65. pmc Modes of resistance to anti-angiogenic therapy
    Gabriele Bergers
    University of California, San Francisco, Department of Neurological Surgery, Brain Tumour Research Center, San Francisco, California 94143, USA
    Nat Rev Cancer 8:592-603. 2008
    ....
  66. ncbi Untangling the ErbB signalling network
    Y Yarden
    Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel
    Nat Rev Mol Cell Biol 2:127-37. 2001
    ..Likewise, small-molecule enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clinical testing. What can this pathway teach us about translating basic science into clinical use?..
  67. ncbi Gene silencing in cancer in association with promoter hypermethylation
    James G Herman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA
    N Engl J Med 349:2042-54. 2003
  68. ncbi Cancer statistics, 2009
    Ahmedin Jemal
    Cancer Surveillance, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia 30303 1002, USA
    CA Cancer J Clin 59:225-49. 2009
    ..Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population and by supporting new discoveries in cancer prevention, early detection, and treatment...
  69. ncbi Wnt signalling in stem cells and cancer
    Tannishtha Reya
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nature 434:843-50. 2005
    ....
  70. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
    ....
  71. ncbi Diverse somatic mutation patterns and pathway alterations in human cancers
    Zhengyan Kan
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 466:869-73. 2010
    ..Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets...
  72. ncbi Vascular endothelial growth factor: basic science and clinical progress
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Endocr Rev 25:581-611. 2004
    ..Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration...
  73. pmc Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
    G L Semenza
    Vascular Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Oncogene 29:625-34. 2010
    ....
  74. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
    ....
  75. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  76. ncbi Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Helen E Bryant
    The Institute for Cancer Studies, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Nature 434:913-7. 2005
    ..The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment...
  77. ncbi Cell cycle, CDKs and cancer: a changing paradigm
    Marcos Malumbres
    Cell Division and Cancer Group, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas CNIO, 28029 Madrid, Spain
    Nat Rev Cancer 9:153-66. 2009
    ..Emerging evidence suggests that tumour cells may also require specific interphase CDKs for proliferation. Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias...
  78. doi Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  79. ncbi Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, United Kingdom
    N Engl J Med 361:123-34. 2009
    ..We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor...
  80. ncbi The global health burden of infection-associated cancers in the year 2002
    Donald Maxwell Parkin
    Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Headington, UK
    Int J Cancer 118:3030-44. 2006
    ..The attributable fraction at the specific sites varies from 100% of cervix cancers attributable to the papilloma viruses to a tiny proportion (0.4%) of liver cancers (worldwide) caused by liver flukes...
  81. pmc Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
    William H Chappell
    Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, USA
    Oncotarget 2:135-64. 2011
    ..Inhibitors targeting these pathways have many potential uses from suppression of cancer, proliferative diseases as well as aging...
  82. ncbi Advances in understanding cancer genomes through second-generation sequencing
    Matthew Meyerson
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nat Rev Genet 11:685-96. 2010
    ..This Review focuses on the methodological considerations for characterizing somatic genome alterations in cancer and the future prospects for these approaches...
  83. pmc PI3K pathway alterations in cancer: variations on a theme
    T L Yuan
    Department of Systems Biology, Harvard Medical School and Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 2115, USA
    Oncogene 27:5497-510. 2008
    ..In this review, we will examine the oncogenic properties of these genetic alterations to understand whether they are redundant or distinct and propose treatment strategies tailored for these genetic lesions...
  84. pmc A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells
    Ulrike Burk
    Department of Visceral Surgery, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    EMBO Rep 9:582-9. 2008
    ..Alternatively, depending on the environmental trigger, this loop might switch and induce epithelial differentiation, and thus explain the strong intratumorous heterogeneity observed in many human cancers...
  85. ncbi Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
    H Maeda
    Department of Microbiology, Kumamoto University School of Medicine, Honjo 2 2 1, Kumamoto, Japan
    J Control Release 65:271-84. 2000
    ..Tumor-specific vascular physiology is also described...
  86. pmc Targeting microRNAs in cancer: rationale, strategies and challenges
    Ramiro Garzon
    Division of Haematology and Oncology, Department of Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43221, USA
    Nat Rev Drug Discov 9:775-89. 2010
    ..In this Review, we describe the role of miRNAs in tumorigenesis and critically discuss the rationale, the strategies and the challenges for the therapeutic targeting of miRNAs in cancer...
  87. ncbi Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
    ....
  88. ncbi Cancer cell metabolism: Warburg and beyond
    Peggy P Hsu
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology Department of Biology, Cambridge, MA 02142, USA
    Cell 134:703-7. 2008
    ..In this Essay, we re-examine the Warburg effect and establish a framework for understanding its contribution to the altered metabolism of cancer cells...
  89. ncbi Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
    P J Roberts
    Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7295, USA
    Oncogene 26:3291-310. 2007
    ..In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease...
  90. pmc The basics of epithelial-mesenchymal transition
    Raghu Kalluri
    Division of Matrix Biology, Beth Israel Deaconess Medical Center, and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Invest 119:1420-8. 2009
    ..The identification of the signaling pathways that lead to activation of EMT programs during these disease processes is providing new insights into the plasticity of cellular phenotypes and possible therapeutic interventions...
  91. pmc DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence
    Olga V Leontieva
    Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC, L3 312, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Aging (Albany NY) 2:924-35. 2010
    ..We conclude that induction of p53 does not activate the senescence program in quiescent cells. In cells with induced p53, re-activation of mTOR by serum stimulation causes senescence, as an equivalent of cellular growth...
  92. ncbi Integrins in cancer: biological implications and therapeutic opportunities
    Jay S Desgrosellier
    Department of Pathology, Moores University of California at San Diego Cancer Center, La Jolla, 92093 0803, United States
    Nat Rev Cancer 10:9-22. 2010
    ..These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment...
  93. pmc IDH1 and IDH2 mutations in gliomas
    Hai Yan
    Department of Pathology, Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 360:765-73. 2009
    ....
  94. pmc VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
    Rosandra N Kaplan
    Department of Pediatrics and the Children s Blood Foundation Laboratories, Weill Cornell Medical College of Cornell University, New York, New York 10021, USA
    Nature 438:820-7. 2005
    ..These findings demonstrate a requirement for VEGFR1+ haematopoietic progenitors in the regulation of metastasis, and suggest that expression patterns of fibronectin and VEGFR1+VLA-4+ clusters dictate organ-specific tumour spread...
  95. ncbi Taking dendritic cells into medicine
    Ralph M Steinman
    The Rockefeller University, New York 10065, USA
    Nature 449:419-26. 2007
    ..Here we present some medical implications of DC biology that account for illness and provide opportunities for prevention and therapy...
  96. ncbi Reflecting on 25 years with MYC
    Natalie Meyer
    Amgen Canada, Inc Mississauga, Ontario, Canada
    Nat Rev Cancer 8:976-90. 2008
    ..Here we chronicle the major advances in our understanding of MYC biology, and peer into the future of MYC research...
  97. ncbi Insulin and insulin-like growth factor signalling in neoplasia
    Michael Pollak
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Nat Rev Cancer 8:915-28. 2008
    ..Recent results are encouraging and have justified the expansion of many translational research programmes...
  98. ncbi The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
    C J Currie
    School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff Medicentre, Cardiff, CF14 4UJ, UK
    Diabetologia 52:1766-77. 2009
    ..We examined the risk of development of solid tumours in relation to treatment with oral agents, human insulin and insulin analogues...
  99. ncbi The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
    Heather R Christofk
    Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 452:230-3. 2008
    ..These results demonstrate that M2 expression is necessary for aerobic glycolysis and that this metabolic phenotype provides a selective growth advantage for tumour cells in vivo...
  100. ncbi Multidrug resistance in cancer: role of ATP-dependent transporters
    Michael M Gottesman
    Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 2:48-58. 2002
    ..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
  101. ncbi Macrophage diversity enhances tumor progression and metastasis
    Bin Zhi Qian
    Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cell 141:39-51. 2010
    ..Specialized subpopulations of macrophages may represent important new therapeutic targets...

Research Grants74

  1. Sutureless Laparoscopic Partial Nephrectomy Using Laser Tissue Welding: Preclinic
    Yasmin Wadia; Fiscal Year: 2013
    ..needs are sealing of solid visceral organs (liver, kidney, pancreas and spleen) involved in polytrauma, and neoplasms;spinal cord and nerve reattachment;sterilization of contaminated wounds, sealing of dural, esophageal and ..
  2. Rac GTPase signaling during embryonic salivary gland branching morphogenesis
    Sharon Sequeira; Fiscal Year: 2012
    ..in a majority of patients treated for salivary gland diseases such as Sjvgren's syndrome (SS), salivary neoplasms, adults being treated for head and neck cancer and those taking medications with anti-sialogogue sequelae...
  3. Molecular Regulation of Progesterone Synthesis
    John S Davis; Fiscal Year: 2013
    ..ovarian steroid secretion are hypertension, diabetes, obesity, osteoporosis, polycystic ovary syndrome and neoplasms of the colon, breast, ovary, and uterus...
  4. Cell signaling as a leukemia biomarker
    JAMES WILLIAM JACOBBERGER; Fiscal Year: 2013
    ..to monitor patients with pre-leukemic conditions like myelodysplastic syndrome (MDS) and myeloid proliferative neoplasms (MPN) for early detection of leukemic transition...
  5. Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
    RONALD JAY KOENIG; Fiscal Year: 2013
    ..Gene expression profiling of PPFP thyroid cancers (compared to all other benign and malignant thyroid neoplasms) resulted in the identification of a PPFP cancer gene signature...
  6. PRE- AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY
    J Evan Sadler; Fiscal Year: 2013
    ..immunodeficiency and leukemia viruses;epithelial morphogenesis;pathogenesis of leukemia, MDS, myeloproliferative neoplasms, and congenital neutropenia;cell cycle control;programmed cell death in development and malignancy...
  7. Developing a murine model for arsenic-induced skin neoplasm
    Mohammad Athar; Fiscal Year: 2010
    ..relevant murine model and could lead to important advances in mechanism-based chemoprevention of these skin neoplasms in arsenic-exposed humans...
  8. FASEB SRC on Hematopoietic Malignancies
    MICHELLE ALICE KELLIHER; Fiscal Year: 2011
    ..of blood cancers, including acute myeloid leukemia, acute lymphoid leukemia, myeloma, myeloproliferative neoplasms and myeloproliferative diseases...
  9. Nanotheranostics for Early Colorectal Cancer Detection and Treatment
    Jeffrey S Souris; Fiscal Year: 2013
    ..Of particular note is the observation that the most frequently found early neoplasms during routine CRC screenings of people >50 years of age are adenomatous polyps...
  10. ENDOGENOUS MODULATION OF COCHLEAR INJURY
    Leonard P Rybak; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Cisplatin is a potent chemotherapeutic agent widely used to treat malignant neoplasms. Side effects, like ototoxicity compromise the quality of life of cancer survivors...
  11. Identification of novel target genes for polycythemia vera (PV)
    Shaoguang Li; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The JAK2V617F mutation is found in the majority of myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia and primary myelofibrosis...
  12. Fatty acid desaturase activity, fish oil and colorectal cancer chemoprevention
    Harvey J Murff; Fiscal Year: 2013
    ..cyclo-oxygenase pathway to prostaglandin E2 (PGE2), an inflammatory eicosanoid aberrantly produced in colorectal neoplasms while EPA is converted to the anti-inflammatory prostaglandin E3 (PGE3)...
  13. Novel Glycosaminoglycan Ethers for Prevention of Metastasis
    Alana L Welm; Fiscal Year: 2011
    ..We propose to develop anionic, partially lipophilic hyaluronic acid derivatives as a synthetic, low anticoagulant, sulfated polysaccharide approach to inhibiting metastatic spread from neoplasms.
  14. Role of Autophagy in Cancer
    Eileen White; Fiscal Year: 2013
    ..Oncocytomas are rare, predominantly benign neoplasms that arise in epithelial tissues that are characterized by the accumulation of large numbers of respiration-..
  15. Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia
    BENJAMIN BRAUN; Fiscal Year: 2013
    ..Thus, they have features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN)...
  16. Anti-Aging Mitochondrial Protein Therapy for Alzheimer?s Disease and Sarcopenia
    JAMES PEPPER BENNETT; Fiscal Year: 2010
    ..starting at 24 months) with rhTFAM therapy have improved motor function as well as lower incidence of liver neoplasms. At 30 months the treated mice have significantly increased motor performance and endurance (by 25% in rotarod ..
  17. Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells
    John H Sampson; Fiscal Year: 2013
    ..is a tumor-specific mutation of the epidermal growth factor receptor that is expressed in GBMs and several other neoplasms. We have previously shown that EGFRvIII can be recognized by highly avid antibodies, so have developed human and ..
  18. Gene Targeted Therapy of Brain Tumors
    John H Sampson; Fiscal Year: 2010
    Primary malignant brain tumors, like glioblastoma (GBM), remain universally fatal. Like most neoplasms, they develop through the acquisition of multiple genetic alterations that lead to a heterogeneous deregulation of cell signaling ..
  19. Role of Genetic Susceptibility in Therapy-related Subsequent Malignancies
    Smita Bhatia; Fiscal Year: 2013
    ..Subsequent malignant neoplasms (SMNs) are one of the most devastating adverse events faced by cancer survivors, and are a leading cause of non- ..
  20. Pathophysiology of Adult T-cell Leukemia/Lymphoma
    UTPAL P DAVE; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Adult T-cell leukemia/lymphoma (ATLL) like most T-cell neoplasms is in dire need of novel therapeutic advances...
  21. NAC for melanoma chemoprevention
    Douglas Grossman; Fiscal Year: 2010
    ..cancer that, under the influence of ultraviolet (UV) radiation, arises from isolated melanocytes or melanocytic neoplasms (moles or nevi)...
  22. NYU Lung Cancer Biomarker Center
    William N Rom; Fiscal Year: 2013
    ..22 thoracic neoplasms were diagnosed with 18 lung adenocarcinomas...
  23. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2012
    ..Nearly all individuals of fair skin bear multiple benign melanocytic neoplasms (nevi) expressing pro- oncogenic mutations in the MAPK pathway, usually in the BRAF or NRAS genes...
  24. MOLECULAR PATHOGENESIS OF HYPERPARATHYROIDISM
    Andrew Arnold; Fiscal Year: 2012
    ..mechanisms might be especially important in parathyroid tumors, possibly explaining why these cyclin D1-driven neoplasms are almost always benign in marked contrast with the malignant features of other cyclin D1-induced tumors, and ..
  25. Inhibition of Histone Deacetylase in Myeloproliferative Neoplasms
    Golam Mohi; Fiscal Year: 2012
    ..The data generated from these studies will lay the groundwork for Phase I and II clinical trials of vorinostat in MPNs. ..
  26. Development and Pilot Test of an Elective BSO Decision Support Guide
    Miriam Kuppermann; Fiscal Year: 2010
    ..the risk of ovarian cancer and/or to avoid possible morbidities and future surgery related to benign ovarian neoplasms, endometriosis, and pelvic pain...
  27. Gut L-Histidine Metabolism and Histamine Signaling in Colonic Neoplasia
    James Versalovic; Fiscal Year: 2013
    ..signaling pathways, and suppression of inflammation may alter predisposition to cancer, specifically colorectal neoplasms. Bacterial genes in the microbiome encode for enzymes that perform biochemical conversion of dietary amino acids ..
  28. Function of calcium exchangers in vetebrate pigmentation
    KEITH CHI CHENG; Fiscal Year: 2010
    Cells containing melanin pigmentation aid vision, protect against UV radiation, and can transform into neoplasms. This proposal is based upon three related discoveries in our lab...
  29. Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention
    Roberd Bostick; Fiscal Year: 2009
    ..calcium and vitamin D, in modulating a plausible panel of molecular phenotypic biomarkers of risk for colorectal neoplasia, and determining whether this modulation predicts reduced recurrence of colorectal neoplasms.
  30. DNA Methyltrasferase Gene Expression in Colon Cancer
    Stephen B Baylin; Fiscal Year: 2013
    ..The first aim focuses on SOX17, newly discovered to be DNA hypermethylated in ~90% of pre-invasive colon neoplasms. It encodes a protein essential for gut endoderm differentiation which inhibits, in the nucleus, Wnt pathway ..
  31. Role of TET proteins in myeloid malignancies
    Anjana Rao; Fiscal Year: 2013
    ..reported that TET2 mutations are frequently associated with myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and myeloid malignancies such as chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)...
  32. Spatiotemporal control of recombination by the RAG proteins and ATM
    JANE AMANDA SKOK; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Lymphoid neoplasms are among the most common malignancies in humans, and, for reasons that remain obscure;their incidence has been increasing over the past two decades...
  33. Isolation and characterization of the normal and cancer stem cells of the tongue.
    Agnieszka Kobielak; Fiscal Year: 2012
    ..The incidence of a subset of neoplasms originating from the oral cavity and the oropharynx, however, in young adults, age <40, has been steadily and ..
  34. Role of Periostin in Polycystic Kidney Disease
    Darren P Wallace; Fiscal Year: 2013
    ..Although cysts are benign neoplasms, they ultimately cause renal insufficiency through extensive nephron loss and replacement of adjacent parenchyma ..
  35. Mechanisms of CDX2 regulation of the IGF axis
    Duyen Dang; Fiscal Year: 2013
    ..As such, studying how CDX2 functions would provide insights into the development and progression of colonic neoplasms. This proposal advances on the concept that CDX2 regulates the IGF axis, depending on cellular p53 status...
  36. Phenotyping pain in a mouse model of pancreatic cancer
    Brian M Davis; Fiscal Year: 2012
    ..This nerve-cancer interaction may also contribute to the aggressive behavior of pancreatic neoplasms. Together these findings suggest an intimate relationship between the peripheral nervous system and pancreatic ..
  37. Meningioma: Risk Factors and Quality of Life
    Melissa L Bondy; Fiscal Year: 2010
    ..the epidemiology of intracranial meningiomas, a lesion which accounts for up to 25% of all primary intracranial neoplasms. We propose to conduct a population-based case/control study of meningioma within the states of Connecticut, ..
  38. Meningioma: Risk Factors and Quality of Life
    Peter M Black; Fiscal Year: 2010
    ..the epidemiology of intracranial meningiomas, a lesion which accounts for up to 25% of all primary intracranial neoplasms. We propose to conduct a population-based case/control study of meningioma within the states of Connecticut, ..
  39. Meningioma: Risk Factors and Quality of Life
    Elizabeth B Claus; Fiscal Year: 2010
    ..the epidemiology of intracranial meningiomas, a lesion which accounts for up to 25% of all primary intracranial neoplasms. We propose to conduct a population-based case/control study of meningioma within the states of Connecticut, ..
  40. Meningioma: Risk Factors and Quality of Life
    Joellen M Schildkraut; Fiscal Year: 2010
    ..the epidemiology of intracranial meningiomas, a lesion which accounts for up to 25% of all primary intracranial neoplasms. We propose to conduct a population-based case/control study of meningioma within the states of Connecticut, ..
  41. Meningioma: Risk Factors and Quality of Life
    JOSEPH LEO WIEMELS; Fiscal Year: 2010
    ..the epidemiology of intracranial meningiomas, a lesion which accounts for up to 25% of all primary intracranial neoplasms. We propose to conduct a population-based case/control study of meningioma within the states of Connecticut, ..
  42. Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's Sarcom
    Vicente Notario; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Tumors of the Ewing's sarcoma family (ESFT) are solid, highly malignant neoplasms of the bone and soft tissues that most often affect children and adolescents, being the second most common bone ..
  43. Regulation of Inflammation-Associated Epithelial Cancer Development
    Lisa Marie Coussens; Fiscal Year: 2012
    ..for initiation and/or maintenance of chronic inflammatory pathways that potentiate growth of developing neoplasms are not well understood...
  44. TRANSCRIPTIONAL REGULATION OF BREAST CANCER METASTASIS
    Zena Werb; Fiscal Year: 2012
    ..We postulate that GATA-3 maintains the differentiation of breast neoplasms, and its loss plays a causal role in malignant progression: During neoplastic progression, GATA-3 maintains ..
  45. Regulation of apoptosis in osteoblasts by Runx2 and NFkB
    Roman Eliseev; Fiscal Year: 2013
    ..Our long-term goal is to elucidate the mechanisms of disregulation of apoptosis in bone neoplasms and find novel treatments targeted at modulation of apoptosis in neoplasia...
  46. Novel Mechanisms of C-Kit Regulation in Mast Cells
    Reuben Kapur; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Myeloproliferative neoplasms or MPNs are a heterogeneous group of complex hematologic diseases, which share the common characteristic of myeloid cell overproduction...
  47. Oral Mucosa Barrier and Bisphosphonate-related Osteonecrosis of the Jaw
    Ichiro Nishimura; Fiscal Year: 2013
    ..by applicant): Bisphosphonate (BP) treatment has been shown to be effective in the management of malignant neoplasms that reside in or metastasize to bone, including multiple myeloma and breast or prostate cancer, respectively...
  48. Gene Expression in Myeloma Cells
    Laurel A Eckhardt; Fiscal Year: 2010
    ..hypermutation and class-switch recombination is a contributing factor, if not the initiating factor, in numerous neoplasms arising within the B lymphoid compartment...
  49. Pancreatic Cancer Management by Novel Gene Therapy &Dietary Agents
    Paul B Fisher; Fiscal Year: 2012
    ..present proposal describes a combinatorial approach of a dietary agent (POH) and adenovirus-based gene therapy, expressing mda-7/IL-24, as chemopreventive and therapeutic regimens for one of the deadliest neoplasms, pancreatic cancer.
  50. The Role of NPM-ALK Signaling in Tumor Cell Metabolism
    SCOTT RP MCDONNELL; Fiscal Year: 2012
    ..Finally, Aim 3 will investigate the metabolic signature of NPM-ALK driven neoplasms. Here, a metabolomics approach will be pursued to characterize the global metabolic changes induced by NPM-ALK ..
  51. The role of Ndy1 in epigenetic gene silencing and stem cell biology
    Philip N Tsichlis; Fiscal Year: 2010
    ..Our studies have linked Ndy1 to the induction of retrovirus-induced rodent hematopoietic neoplasms. Moreover, examination of its expression in existing databases has shown that Ndy1 is overexpressed in a variety ..
  52. Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
    Aaron P Rapoport; Fiscal Year: 2013
    ..and functional then this combination strategy of ASCT followed by adoptive transfer of "redirected" autologous T-cells could be a platform for effective post-transplant immunotherapy of myeloma and perhaps other hematologic neoplasms.
  53. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ..hematological malignancies (leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms) and non-malignant hematology (bleeding and clotting disorders and diseases of red blood cells)...
  54. MicroRNA Deregulation in JAK2V617F-positive Chronic Myeloid Neoplasms
    Huichun Zhan; Fiscal Year: 2013
    ....
  55. STAT1 Activation and HPP1 Tumor Suppression
    David Shibata; Fiscal Year: 2013
    ..recently identified gene that was initially discovered by virtue of its significant downregulation in colorectal neoplasms derived from patients with Hyperplastic Polyposis...
  56. The Role of Semaphorin 4D and Plexin-B1 in Tumor-Induced Angiogenesis.
    John R Basile; Fiscal Year: 2013
    ..provided by applicant): Oral cancer is common among men in the developed world and among the most difficult neoplasms to treat...
  57. Translational Development of Replication-Competent Retrovirus Vectors
    Noriyuki Kasahara; Fiscal Year: 2013
    ..brain tumor in adults, accounting for 50-60% of primary brain tumors, and 7-10% of childhood intracranial neoplasms. Despite major improvements in neuroimaging, neurosurgery, radiotherapy, and supportive care, the overall ..
  58. JAK2 signaling in erythropoiesis
    LILY JUNSHEN HUANG; Fiscal Year: 2013
    ..multiple lineages, and a gain-of-function JAK2 mutation, V617F, is the major determinant in myeloproliferative neoplasms (MPNs)...
  59. Targeting Fra-1 in Toxicant-Induced Lung Tumor Initiation &Development
    Sekhar P Reddy; Fiscal Year: 2012
    ..Thus, we will examine for the first time the specific roles of Fra-1 in lung neoplasms using mice with a Fra-1 "floxed" allele to conditionally delete Fra- 1 in lung cell types...
  60. A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
    Brenda M Birmann; Fiscal Year: 2013
    ..provided by applicant): Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of >30 lymphoid neoplasms, >85% of which are of B cell lineage...
  61. Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance
    Warren D Shlomchik; Fiscal Year: 2013
    ..Unfortunately, most other neoplasms are relatively GVL-resistant...
  62. Dietary, Hormonal, and Lifestyle Factors and Risk of Primary Hyperparathyroidism
    Julie Paik; Fiscal Year: 2010
    ..The parathyroid adenomas of sporadic primary hyperparathyroidism are monoclonal, suggesting that these neoplasms originate from single cells with a growth conferring mutation...
  63. Glial Dysfunction in Ataxia Telangiectasia
    Margot Mayer Proschel; Fiscal Year: 2009
    ..neuropathy, infertility, translocations of chromosomes 7 and 14, underdeveloped thymus, and increased risk of neoplasms leading to poor quality of life...
  64. HISTOMETRIC ANALYSIS OF PREMALIGNANT ENDOMETRIAL LESIONS
    Francisco Garcia; Fiscal Year: 2003
    ..It accounts for about 36,000 cases of invasive cancer each year and is among the top five neoplasms affecting women...
  65. Effect of chronic low-dose phthalate exposure on the immature primate testis
    Ina Dobrinski; Fiscal Year: 2009
    ..to human health and has been implicated in both the apparent decline of male fertility and a rise in testicular neoplasms. Phthalate esters are widely used as plasticizers in consumer products and can leach into the environment, ..
  66. NON-GASTRIN ACID SECRETAGOGUE IN ISLET CELL TUMORS
    William Chey; Fiscal Year: 1990
    In a group of patients with pancreatic islet cell neoplasms, marked gastric acid hypersecretion and peptic ulceration and/or diarrhea, normal plasma concentrations of gastrin were found...
  67. MOLECULAR MARKERS OF PROGNOSIS IN MEDULLOBLASTOMA
    SANDRA BIGNER; Fiscal Year: 2000
    ..hindered by technical inabilities to discriminate prospectively between patients with aggressive and indolent neoplasms. Recent advances in molecular biology, cytogenetics, and immunohistochemistry now convincingly demonstrate the ..
  68. CARCINOGENICITY OF 2-NITROPROPANE--A PROBABLE MECHANISM
    Emerich Fiala; Fiscal Year: 2000
    ..of 2-NP, thereby obtaining information for predicting whether or not the compound could also cause neoplasms in man...
  69. Microarray analysis of thyroid neoplasm
    Martha Zeiger; Fiscal Year: 2004
    ..Because the surgical management for benign and malignant thyroid neoplasms differ, patients with suspicious FNAs may be treated in a less than ideal fashion surgically...
  70. ACTIVE SPECIFIC IMMUNOTHERAPY IN MAN--A MURINE MODEL
    Barry Kahan; Fiscal Year: 1992
    ..6 mm) or 14 (10 mm) day established MCA-F subcutaneous neoplasms, and almost vitiated spontaneous pulmonary metastases following amputation of a limb bearing the MCA-F-4 (lung ..
  71. Influence of acid reflux on stromal epithelial interaction in Barrett?s esophagus
    GANAPATHY PRASAD; Fiscal Year: 2009
    ..Myofibroblast derived growth factors are known to promote proliferation of epithelial neoplasms 5-7...
  72. PHEOCHROMOCYTOMAS FROM NEUROFIBROMATOSIS KNOCKOUT MICE
    Arthur Tischler; Fiscal Year: 2003
    ..Pheochromocytomas are developmentally related to neuroblastomas, which are common adrenal medullary neoplasms, and pheochromocytoma cells can undergo neuronal differentiation...
  73. Functional analysis of the CYLD tumor suppressor
    JULIDE CELEBI; Fiscal Year: 2009
    ..have been demonstrated in families with FC, and loss of heterozygosity at the CYLD locus has been found in these neoplasms, suggesting that CYLD functions as a tumor suppressor...
  74. In Vivo Detection of Flat Colorectal Neoplasms with CT Colonography
    JANNE JOHANNES NAPPI; Fiscal Year: 2010
    ..Most colorectal cancers develop from sessile or pedunculated polypoid neoplasms. Early removal of such neoplasms has been observed to reduce the occurrence of colorectal carcinoma...